This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo's (MASI) Rad-G Pulse Oximeter Receives FDA Clearance
by Zacks Equity Research
Masimo's (MASI) Rad-G Pulse Oximeter receives FDA clearance, thereby allowing clinicians to access the most accurate and reliable pulse oximetry monitoring technologies.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $105.19 in the latest trading session, marking a +0.72% move from the prior day.
3 Great MedTech Stocks to Pick Amid the Coronavirus Crisis
by Sriparna Ghosal
Backed by projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Abbott's MitraClip G4 Receives CE Mark for Treatment of MR
by Zacks Equity Research
Abbott's (ABT) MitraClip G4 is expected to improve MR patients' quality of life post its usage eligibility in Europe and other countries recognizing the CE Mark.
Abbott (ABT) Stock Moves -1.98%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $102.73, moving -1.98% from the previous trading session.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Abbott Launches Sports Biosensor in Europe, Boosts CGM Wing
by Zacks Equity Research
Abbott (ABT) makes its first non-exclusive collaboration with Atlanta-based sports technology company, Supersapiens.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $106.66 in the latest trading session, marking a +0.91% move from the prior day.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $104.70 in the latest trading session, marking a +0.67% move from the prior day.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
Top Research Reports for Disney, Novo Nordisk & BHP
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).
Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy
by Zacks Equity Research
Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.
Abbott (ABT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $104.16 in the latest trading session, marking a -1.3% move from the prior day.
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric
3 Coronavirus-Led Threats to MedTech That May Linger
by Urmimala Biswas
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics
Market Waits for Major Economic Data This Week
by Zacks Equity Research
Market Waits for Major Economic Data This Week.
Big Week of Econ Data Starts on a Lull
by Mark Vickery
Although this will be a big week for economic data, today sees nothing new on this front.
Coronavirus Impact on Consumer Behavior
by Sheraz Mian
The need to limit infections from Covid-19 will result in permanent social-distancing regulations that dramatically impact most industries in all countries.